In a nutshell This study looked at the use of olaparib (Lynparza) treatment for patients with high risk, BRCA1/2-positive, HER2-negative breast cancer (BC). The authors found that in patients with BRCA1/2-positive BC, olaparib after local treatment improved the outcomes of these patients. Some background BC is one of the most common cancers...
Read More
In a nutshell This study looked at whether age is related to a risk of poor outcomes in men undergoing delayed radical prostatectomy (RP; prostate removal surgery) following active surveillance (AS). The authors found that older patients require closer monitoring when on AS and may require additional testing to identify the progression of their...
Read More
In a nutshell This study evaluated whether liraglutide (Victoza) improves diabetic control in patients with difficult to control type 2 diabetes (T2D) and if there were certain factors that influence the effects of liraglutide. It found that patients responded equally well to liraglutide regardless of body mass index (BMI; a measurement of...
Read More
In a nutshell This study evaluated the safety and effectiveness of dual chimeric antigen receptor (CAR) T-cell therapy for patients with recurrent or hard-to-treat B-cell non-Hodgkin lymphoma (NHL). This study found that this treatment was safe and effective for these patients. Some background B-cell non-Hodgkin’s lymphoma (NHL) is one of...
Read More
In a nutshell This study looked at the safety and effectiveness of tirzepatide (LY-3298176) in patients with type 2 diabetes (T2D) inadequately controlled by diet and exercise alone. It found that compared to placebo, tirzepatide improved diabetes control and weight in these patients. Some background In T2D, there is a resistance of the...
Read More
In a nutshell The study aimed to evaluate the effectiveness and safety of combining standard-dose pembrolizumab (PEM; Keytruda) with two different doses of ipilimumab (IPI; Yervoy) in patients with advanced melanoma. The study concluded that 200 mg PEM plus 50 mg of IPI showed good effectiveness and reduced toxicity compared to 100 mg...
Read More
In a nutshell This study evaluated the effectiveness and safety of idelalisib (Zydelig) combined with rituximab (Rituxan) in the treatment of patients with chronic lymphocytic leukemia (CLL) in a real-world setting. The data supported the effectiveness of this regimen in routine practice for these patients. Some background Idelalisib (IDL) is an...
Read More
In a nutshell This study evaluated the effect of different surgical interventions on sexual function in patients with benign prostatic obstruction (BPO). The authors concluded that the prostatic urethral lift (PUL) intervention provided significantly improved erectile function at 24 months. Some background Benign prostatic obstruction (BPO) is an...
Read More
In a nutshell This study investigated the clinical benefits and safety of FMS-like tyrosine kinase 3 inhibitors (FLT3i) in various treatment stages of acute myeloid leukemia (AML). The data showed that FLT3is safely improved prognosis in the induction stage (first-line treatment) of newly diagnosed FLT3-positive AML and salvage therapy (treatment...
Read More
In a nutshell This study investigated the effectiveness and safety outcomes of nivolumab (Opdivo) in combination with carboplatin (C; Paraplatin) and paclitaxel (P; Taxol) plus bevacizumab (B; Avastin) as first-line treatment for patients with advanced non-squamous non-small cell lung cancer (NSCLC). The data showed that nivolumab plus BCP...
Read More
In a nutshell This study reported the long-term effectiveness and safety of the combined treatment of vemurafenib (Zelboraf) and cobimetinib (Cotellic) in patients with previously untreated BRAF-mutated advanced melanoma. The data showed that the combination was safe and effective over the long term. Some background Melanoma is an aggressive...
Read More
In a nutshell This study evaluated the effectiveness and safety of regorafenib (Stivarga) versus TAS-102 (Lonsurf; trifluridine-tipiracil) for the treatment of patients with unresponsive metastatic colorectal cancer (mCRC). The data showed that both treatments were safe and lead to similar survival outcomes for primary and secondary treatment of...
Read More
